From major journals, first or last author from the Institute for Cancer Research
Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA(2025) Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy Mol Oncol(in press) DOI 10.1002/1878-0261.70117, PubMed 40852937
Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J(2025) Targeting the roots of myeloid malignancies with T cell receptors Nat Rev Cancer(in press) DOI 10.1038/s41568-025-00857-0, PubMed 40841587
Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O(2025) High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy Breast Cancer Res, 27(1), 143 DOI 10.1186/s13058-025-02092-9, PubMed 40790765
Sagini K, Selvarajah M, Romero S, Bassols-Citores E, Martin-Gracia B, Ramirez-Garrastacho M, Rise F, Endzeliņš E, Sadovska L, Skorinkina D, Boguševiča M, Cešeiko R, Čampa M, Klavina A, Linē A, Llorente A(2025) The Redox Enzyme Thioredoxin Is Increased in Plasma Extracellular Vesicles From Endurance-Trained Females in Response to Acute Exercise FASEB J, 39(16), e70927 DOI 10.1096/fj.202500678R, PubMed 40810354
Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA(2025) Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy Mol Oncol(in press) DOI 10.1002/1878-0261.70117, PubMed 40852937
Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J(2025) Targeting the roots of myeloid malignancies with T cell receptors Nat Rev Cancer(in press) DOI 10.1038/s41568-025-00857-0, PubMed 40841587
